Cost-effectiveness of new therapies in first-line treatment of advanced melanoma for patients with independent BRAF mutation status from a Brazilian private payer perspective.

被引：1

作者：

Matteucci, Christina

Lima, Joao P. S. D. N.

Bernardino, Graziela

Oliveira, Ana Paula

Maia, Daniela Galdeano

机构：

[1] BMS, Sao Paulo, Brazil

[2] AC Camargo Canc Ctr, Sao Paulo, Brazil

[3] Bristol Myers Squibb, Sao Paulo, Brazil

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.e21546

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21546

引用

页数：1